ERCC6 and cancer: While no specific CSB or CSA inhibitors are in clinical use, there is evidence that inhibiting transcription itself during therapy, for example, using CDK9 (cell cycle-dependent kinase 9) inhibitors to pause transcription globally can make DNA damage more toxic to cancer cells by preventing TCR, akin to a transcription-coupled sensitization strategy [95].